269 related articles for article (PubMed ID: 35585670)
21. Identification of Novel RAS Signaling Therapeutic Vulnerabilities in Diffuse Intrinsic Pontine Gliomas.
Koncar RF; Dey BR; Stanton AJ; Agrawal N; Wassell ML; McCarl LH; Locke AL; Sanders L; Morozova-Vaske O; Myers MI; Hamilton RL; Carcaboso AM; Kohanbash G; Hu B; Amankulor NM; Felker J; Kambhampati M; Nazarian J; Becher OJ; James CD; Hashizume R; Broniscer A; Pollack IF; Agnihotri S
Cancer Res; 2019 Aug; 79(16):4026-4041. PubMed ID: 31201162
[TBL] [Abstract][Full Text] [Related]
22. Functionally defined therapeutic targets in diffuse intrinsic pontine glioma.
Grasso CS; Tang Y; Truffaux N; Berlow NE; Liu L; Debily MA; Quist MJ; Davis LE; Huang EC; Woo PJ; Ponnuswami A; Chen S; Johung TB; Sun W; Kogiso M; Du Y; Qi L; Huang Y; Hütt-Cabezas M; Warren KE; Le Dret L; Meltzer PS; Mao H; Quezado M; van Vuurden DG; Abraham J; Fouladi M; Svalina MN; Wang N; Hawkins C; Nazarian J; Alonso MM; Raabe EH; Hulleman E; Spellman PT; Li XN; Keller C; Pal R; Grill J; Monje M
Nat Med; 2015 Jun; 21(6):555-9. PubMed ID: 25939062
[TBL] [Abstract][Full Text] [Related]
23. Intraarterial delivery of bevacizumab and cetuximab utilizing blood-brain barrier disruption in children with high-grade glioma and diffuse intrinsic pontine glioma: results of a phase I trial.
McCrea HJ; Ivanidze J; O'Connor A; Hersh EH; Boockvar JA; Gobin YP; Knopman J; Greenfield JP
J Neurosurg Pediatr; 2021 Aug; 28(4):371-379. PubMed ID: 34359048
[TBL] [Abstract][Full Text] [Related]
24. DIPG-like MYB-altered diffuse astrocytoma with durable response to intensive chemotherapy.
Trkova K; Sumerauer D; Krskova L; Vicha A; Koblizek M; Votava T; Priban V; Zapotocky M
Childs Nerv Syst; 2023 Sep; 39(9):2509-2513. PubMed ID: 37165121
[TBL] [Abstract][Full Text] [Related]
25. PNOC015: Repeated convection-enhanced delivery of MTX110 (aqueous panobinostat) in children with newly diagnosed diffuse intrinsic pontine glioma.
Mueller S; Kline C; Stoller S; Lundy S; Christopher L; Reddy AT; Banerjee A; Cooney TM; Raber S; Hoffman C; Luks T; Wembacher-Schroeder E; Lummel N; Zhang Y; Bonner ER; Nazarian J; Molinaro AM; Prados M; Villanueva-Meyer JE; Gupta N
Neuro Oncol; 2023 Nov; 25(11):2074-2086. PubMed ID: 37318058
[TBL] [Abstract][Full Text] [Related]
26. Microtubule-Targeting Combined with HDAC Inhibition Is a Novel Therapeutic Strategy for Diffuse Intrinsic Pontine Gliomas.
Ehteda A; Khan A; Rajakumar G; Vanniasinghe AS; Gopalakrishnan A; Liu J; Tsoli M; Ziegler DS
Mol Cancer Ther; 2023 Dec; 22(12):1413-1421. PubMed ID: 37683275
[TBL] [Abstract][Full Text] [Related]
27. Therapeutic targeting of transcriptional elongation in diffuse intrinsic pontine glioma.
Katagi H; Takata N; Aoi Y; Zhang Y; Rendleman EJ; Blyth GT; Eckerdt FD; Tomita Y; Sasaki T; Saratsis AM; Kondo A; Goldman S; Becher OJ; Smith E; Zou L; Shilatifard A; Hashizume R
Neuro Oncol; 2021 Aug; 23(8):1348-1359. PubMed ID: 33471107
[TBL] [Abstract][Full Text] [Related]
28. TP53 Pathway Alterations Drive Radioresistance in Diffuse Intrinsic Pontine Gliomas (DIPG).
Werbrouck C; Evangelista CCS; Lobón-Iglesias MJ; Barret E; Le Teuff G; Merlevede J; Brusini R; Kergrohen T; Mondini M; Bolle S; Varlet P; Beccaria K; Boddaert N; Puget S; Grill J; Debily MA; Castel D
Clin Cancer Res; 2019 Nov; 25(22):6788-6800. PubMed ID: 31481512
[TBL] [Abstract][Full Text] [Related]
29. Characterization of the immune microenvironment of diffuse intrinsic pontine glioma: implications for development of immunotherapy.
Lieberman NAP; DeGolier K; Kovar HM; Davis A; Hoglund V; Stevens J; Winter C; Deutsch G; Furlan SN; Vitanza NA; Leary SES; Crane CA
Neuro Oncol; 2019 Jan; 21(1):83-94. PubMed ID: 30169876
[TBL] [Abstract][Full Text] [Related]
30. The intersect of neurosurgery with diffuse intrinsic pontine glioma.
Kuzan-Fischer CM; Souweidane MM
J Neurosurg Pediatr; 2019 Dec; 24(6):611-621. PubMed ID: 31786541
[TBL] [Abstract][Full Text] [Related]
31. ALK2 inhibitors display beneficial effects in preclinical models of
Carvalho D; Taylor KR; Olaciregui NG; Molinari V; Clarke M; Mackay A; Ruddle R; Henley A; Valenti M; Hayes A; Brandon AH; Eccles SA; Raynaud F; Boudhar A; Monje M; Popov S; Moore AS; Mora J; Cruz O; Vinci M; Brennan PE; Bullock AN; Carcaboso AM; Jones C
Commun Biol; 2019; 2():156. PubMed ID: 31098401
[TBL] [Abstract][Full Text] [Related]
32. Poly-ADP-Ribose Polymerase as a Therapeutic Target in Pediatric Diffuse Intrinsic Pontine Glioma and Pediatric High-Grade Astrocytoma.
Chornenkyy Y; Agnihotri S; Yu M; Buczkowicz P; Rakopoulos P; Golbourn B; Garzia L; Siddaway R; Leung S; Rutka JT; Taylor MD; Dirks PB; Hawkins C
Mol Cancer Ther; 2015 Nov; 14(11):2560-8. PubMed ID: 26351319
[TBL] [Abstract][Full Text] [Related]
33. Design considerations of an IL13Rα2 antibody-drug conjugate for diffuse intrinsic pontine glioma.
Lian X; Kats D; Rasmussen S; Martin LR; Karki A; Keller C; Berlow NE
Acta Neuropathol Commun; 2021 May; 9(1):88. PubMed ID: 34001278
[TBL] [Abstract][Full Text] [Related]
34. Potent anti-tumor efficacy of palbociclib in treatment-naïve H3.3K27M-mutant diffuse intrinsic pontine glioma.
Sun Y; Sun Y; Yan K; Li Z; Xu C; Geng Y; Pan C; Chen X; Zhang L; Xi Q
EBioMedicine; 2019 May; 43():171-179. PubMed ID: 31060906
[TBL] [Abstract][Full Text] [Related]
35. Fimepinostat Impairs NF-κB and PI3K/AKT Signaling and Enhances Gemcitabine Efficacy in H3.3K27M-Diffuse Intrinsic Pontine Glioma.
Wang D; Yan K; Yu H; Li H; Zhou W; Hong Y; Guo S; Wang Y; Xu C; Pan C; Tang Y; Liu N; Wu W; Zhang L; Xi Q
Cancer Res; 2024 Feb; 84(4):598-615. PubMed ID: 38095539
[TBL] [Abstract][Full Text] [Related]
36. TSPO PET Imaging as a Potent Non-Invasive Biomarker for Diffuse Intrinsic Pontine Glioma in a Patient-Derived Orthotopic Rat Model.
Chevaleyre C; Kereselidze D; Caillé F; Tournier N; Olaciregui NG; Winkeler A; Declèves X; Jego B; Cisternino S; Auvity S; Truillet C
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293329
[TBL] [Abstract][Full Text] [Related]
37. Advances and Clinical Trials Update in the Treatment of Diffuse Intrinsic Pontine Gliomas.
Dalle Ore C; Coleman C; Gupta N; Mueller S
Pediatr Neurosurg; 2023; 58(5):259-266. PubMed ID: 36642062
[TBL] [Abstract][Full Text] [Related]
38. A kinome-wide shRNA screen uncovers vaccinia-related kinase 3 (VRK3) as an essential gene for diffuse intrinsic pontine glioma survival.
Silva-Evangelista C; Barret E; Ménez V; Merlevede J; Kergrohen T; Saccasyn A; Oberlin E; Puget S; Beccaria K; Grill J; Castel D; Debily MA
Oncogene; 2019 Sep; 38(38):6479-6490. PubMed ID: 31324890
[TBL] [Abstract][Full Text] [Related]
39. MRI-guided focused ultrasound enhances drug delivery in experimental diffuse intrinsic pontine glioma.
Ishida J; Alli S; Bondoc A; Golbourn B; Sabha N; Mikloska K; Krumholtz S; Srikanthan D; Fujita N; Luck A; Maslink C; Smith C; Hynynen K; Rutka J
J Control Release; 2021 Feb; 330():1034-1045. PubMed ID: 33188825
[TBL] [Abstract][Full Text] [Related]
40. Laminin-associated integrins mediate Diffuse Intrinsic Pontine Glioma infiltration and therapy response within a neural assembloid model.
Sinha S; Huang MS; Mikos G; Bedi Y; Soto L; Lensch S; Ayushman M; Bintu L; Bhutani N; Heilshorn SC; Yang F
Acta Neuropathol Commun; 2024 May; 12(1):71. PubMed ID: 38706008
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
